- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05312294
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
March 28, 2022 updated by: St. Petersburg Research Institute of Vaccines and Sera
Multicenter, Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
Comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M® Inactivated Split Influenza Vaccine (without preservative) and the Flu-M® vaccine (with preservative) in volunteers aged between 18 and 60
Study Overview
Status
Completed
Conditions
Detailed Description
- Assessment of the tolerability and safety of the Flu-M® inactivated split influenza vaccine (without preservative) and Flu-M® (with preservative).
- Assessment of the immunogenicity of the Flu-M® inactivated split influenza vaccine (with preservative) and Flu-M® (without preservative).
Single administration of the trial products. Duration of follow-up - 28+3 (outpatient visit) and Long-term follow-up - 180±3 days.
Study Type
Interventional
Enrollment (Actual)
654
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Engels, Russian Federation
- State Autonomous Health Institution "Engels City Clinical Hospital No1"
-
Perm, Russian Federation
- Limited Liability Company "Professorskaya Clinica"
-
Saint Petersburg, Russian Federation
- Limited Liability Company "Clinika Zvezdnaya"
-
Saint Petersburg, Russian Federation
- Limited Liability Company "MEDICINSKAYA CLINIKA"
-
Saint Petersburg, Russian Federation
- Limited Liability Company "PeterClinic"
-
Saint Petersburg, Russian Federation
- Limited Liability Company "Scientific Research Center Eco-Safety"
-
Saint Petersburg, Russian Federation
- Saint Petersburg State Budgetary Healthcare Institution "State Polyclinic No. 117"
-
Yaroslavl, Russian Federation
- Limited Liability Company "Medical Center Diagnostics and Prevention Plus"
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteers (men and women) aged 18-60 years;
- Written informed consent of volunteers to participate in the clinical trial;
- Volunteers able to fulfill requirements of the Protocol (i.e. fill out the patient's diary, come to follow-up visits);
- For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception during the trial and at least two months after vaccination
- For fertile men - consent to observe adequate methods of contraception during the trial and at least two months after vaccination, except for men after vasectomy with documented azoospermia, and their sexual partners should use methods of contraception that ensure more than 90% reliability or be incapable of conception after a surgical sterilization or have a natural menopause for at least 2 years.
Exclusion Criteria:
- History of influenza/ARVI or previous influenza vaccination during 6 months before the trial;
- Positive result of the SARS-CoV-2 test;
- A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination);
- Allergic reactions to vaccine components or any previous vaccination;
- History of allergic reaction to chicken protein;
- Guillain-Barré syndrome (acute polyneuropathy) in the medical history;
- Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines;
- Use of any vaccines within 1 month before the vaccination, excluding vaccines according to the National Calendar of Preventive Vaccination, including for epidemic reasons;
- History of leukemia, cancer, autoimmune diseases;
- (Positive blood test results for HIV, syphilis, hepatitis B/C;
- Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial;
- History of long-term use (more than 14 days) of immunosuppressants or immunomodulatory drugs for six months before the trial;
- History of any confirmed or suspected immunosuppressive or immunodeficiency condition;
- History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination);
- Diabetes mellitus, thyrotoxicosis or other diseases of the endocrine system;
- History of eczema;
- Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening);
- Tuberculosis, neurological or mental disorders, a convulsive syndrome, including in the past medical history;
- History of acute infectious diseases (recovery less than 4 weeks before vaccination);
- Consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products;
- Smoking of more than 10 cigarettes per day;
- Participation in another clinical trial during the last 3 months;
- Pregnancy or lactation;
- Coagulopathy, including hemophilia;
- Taking aspirin or other antiplatelet agents in high doses.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FLU-M w/o/p
Volunteers were vaccinated with a single dose of the Flu-M vaccine (without preservative) intramuscularly in a dose of 0.5 mL.
|
Solution for intramuscular injection, 0.5 ml
|
Experimental: FLU-M w/p
Volunteers were vaccinated with a single dose of the Flu-M vaccine (with preservative) intramuscularly in a dose of 0.5 mL.
|
Solution for intramuscular injection, 0.5 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline geometric mean titer ratio of antibodies for each virus strain (GMT (Flu-M w/p) / GMT (Flu-M w/o/p) at 6 months
Time Frame: days 0-180
|
The upper limit of bilateral 95% CI for the GMT ratio (GMT (Flu-M w/p) / GMT (Flu-M w/o/p) should not exceed 1.5
|
days 0-180
|
Change from baseline the difference between seroconversion rates (seroconversion rate Flu-M w/p - seroconversion rate Flu-M w/o/p) at 6 months
Time Frame: days 0-180
|
The upper limit of bilateral 95% CI for the difference between seroconversion rates (seroconversion rate Flu-M w/p - seroconversion rate Flu-M w/o/p) should not exceed 10%
|
days 0-180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean titer of antibodies for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: days 0,28,180
|
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay)
|
days 0,28,180
|
Seroconversion rate for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: days 0,28,180
|
days 0,28,180
|
|
Seroconversion factor for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: days 0,28,180
|
days 0,28,180
|
|
Seroprotection rate for each virus strain (A (H1N1), A (H3N2) and B)
Time Frame: days 0,28,180
|
days 0,28,180
|
|
Incidence, severity, and duration of influenza or ARVI during 6 months after vaccination
Time Frame: days 1-180
|
days 1-180
|
|
Incidence of adverse events (AEs)
Time Frame: days 1-180
|
days 1-180
|
|
Incidence of serious adverse events (SAEs)
Time Frame: days 1-180
|
days 1-180
|
|
Number of patients with abnormal results of blood pressure (BP)
Time Frame: days 0,1,7,28,180
|
BP measurements include the systolic and diastolic blood pressure.BP is measured on the brachial artery according to the Korotkoff method using a certified sphygmomanometer or tonometer.
It is also allowed to use a certified electronic tonometer for measuring.
|
days 0,1,7,28,180
|
Number of patients with abnormal results of heart rate (HR)
Time Frame: days 0,1,7,28,180
|
The HR is measured during auscultation of the heart in parallel with determining the pulse rate on the radial artery (or on the carotid artery in case of weak pulsation in the radial artery) for a minute while sitting.
|
days 0,1,7,28,180
|
Number of patients with abnormal results of respiratory rate (RR)
Time Frame: days 0,1,7,28,180
|
The RR is measured for a minute at rest in the sitting position, by registering the breathing movements of the chest or abdominal wall.
|
days 0,1,7,28,180
|
Number of patients with abnormal results of body temperature (>37 °С)
Time Frame: days 0,1,7,28,180
|
Body temperature (°C) is measured with a mercury or digital thermometer in the armpit for at least 5 minutes or with a non-contact infrared digital thermometer.
|
days 0,1,7,28,180
|
Number of patients with abnormal results of physical examination
Time Frame: days 0,1,7,28,180
|
Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion.
|
days 0,1,7,28,180
|
Number of patients with abnormal results of neurological status
Time Frame: days 0,7,28
|
Assessment of:
|
days 0,7,28
|
Determination of total IgE
Time Frame: days 0,7,28
|
days 0,7,28
|
|
Number of patients with abnormal results of electrocardiography (ECG)
Time Frame: days 0,7
|
2-lead electrocardiography (ECG).
Assessment of: PQ, QT,QTc intervals, QRS complex
|
days 0,7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2020
Primary Completion (Actual)
September 3, 2021
Study Completion (Actual)
November 15, 2021
Study Registration Dates
First Submitted
March 17, 2022
First Submitted That Met QC Criteria
March 28, 2022
First Posted (Actual)
April 5, 2022
Study Record Updates
Last Update Posted (Actual)
April 5, 2022
Last Update Submitted That Met QC Criteria
March 28, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLM-03-2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Flu-M [inactivated split influenza vaccine] without preservative
-
St. Petersburg Research Institute of Vaccines and...Completed
-
St. Petersburg Research Institute of Vaccines and...CompletedInfluenza, Human | Vaccination; Infection | VaccinesRussian Federation
-
St. Petersburg Research Institute of Vaccines and...Completed
-
St. Petersburg Research Institute of Vaccines and...Completed
-
St. Petersburg Research Institute of Vaccines and...Completed
-
St. Petersburg Research Institute of Vaccines and...CompletedInfluenzaRussian Federation
-
St. Petersburg Research Institute of Vaccines and...RecruitingVaccine Reaction | Influenza | Influenza, Human | Influenza Viral InfectionsRussian Federation
-
St. Petersburg Research Institute of Vaccines and...CompletedInfluenza, Human | Vaccination; Infection | VaccinesRussian Federation
-
NovartisNovartis VaccinesCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompleted